STAT1 gain-of-function disease is caused by mutations in the gene encoding signal transducer and activator of transcription 1, a protein that sits at the receiving end of type I interferon signaling. In a healthy immune system, interferons are emergency messengers: when a cell detects viral invasion, it releases interferon, which instructs neighboring cells to switch on hundreds of interferon-stimulated genes that establish an antiviral state. STAT1 is the intracellular relay that carries this instruction from the interferon receptor at the cell surface to the DNA in the nucleus. The gain-of-function mutations lock the relay partially in the on position. Even in the absence of any infection, STAT1 accumulates in the nucleus, interferon-stimulated genes remain constitutively active, and the body behaves as though it is fighting a virus that never clears. The clinical consequences, first systematically described in 2011 and now known to underlie many cases of what was historically called chronic mucocutaneous candidiasis disease, include recurrent fungal and viral infections, autoimmunity, enteropathy, interstitial lung disease, and a strikingly elevated risk of aneurysms and cancers of the immune system. Because the mutation is dominant and acts by amplifying normal signaling rather than destroying the protein, simply removing the gene is not an option, and the condition is often severe enough that hematopoietic stem cell transplantation, with all its risks, has been the only curative approach.

The new work focuses on dendritic cells, the professional antigen-presenting cells that patrol tissues, swallow debris and pathogens, and then travel to lymph nodes to present captured fragments to T lymphocytes. Dendritic cells are uniquely sensitive to type I interferon, which matures them from quiet scouts into inflammatory commanders. In STAT1 gain-of-function, dendritic cells exist in a chronic state of interferon-driven activation, and this chronicity is thought to fuel much of the autoimmune and tissue-destructive pathology seen in patients. The researchers set out to determine whether the inflammatory program in these cells could be disengaged not by blocking interferon signaling directly, but by manipulating the metabolic machinery that fuels it.

The tool they chose was metformin. For decades the first-line therapy for type 2 diabetes, metformin works in large part by inhibiting complex I of the mitochondrial electron transport chain, gently restricting the cell’s capacity to generate ATP through oxidative phosphorylation. The resulting mild energetic stress activates AMP-activated protein kinase, or AMPK, the cell’s fuel gauge, which responds by shifting metabolism toward catabolic, glucose- and fatty-acid-oxidation-based energy production while suppressing anabolic, growth-oriented programs. Over the past fifteen years it has become clear that immune cells are exquisitely dependent on these metabolic switches. Activated dendritic cells normally abandon oxidative phosphorylation in favor of aerobic glycolysis, the rapid-burn sugar metabolism that supports the biosynthetic demands of inflammation. Metformin, by stressing mitochondrial respiration and activating AMPK, counteracts this glycolytic shift and pushes cells back toward a calmer, oxidative metabolic profile.

In their experiments, the researchers used dendritic cells carrying STAT1 gain-of-function mutations and demonstrated that metformin treatment produced what they describe as an immunometabolic rewiring: the drug attenuated the type I interferon-driven inflammatory phenotype that defines the disease state. At the molecular level, this means dampening the constitutive activity of interferon-stimulated genes and reducing the production of the inflammatory mediators that activated dendritic cells normally pour out, including the cytokines and chemokines that recruit and polarize T cells. The study’s central insight is that the pathological interferon signaling in STAT1 gain-of-function is not merely a linear signaling problem that must be blocked at the receptor or at STAT1 itself; it is embedded in, and supported by, a metabolic state that can be pharmacologically disassembled from an entirely different angle.

This angle matters because directly suppressing type I interferon signaling in patients is fraught. JAK inhibitors, which block the kinase signaling downstream of interferon receptors, have shown clinical benefit in STAT1 gain-of-function patients and are increasingly used, but they are broad immunosuppressants that also impair beneficial cytokine pathways, raising infection risks in patients who are already vulnerable. Antifungal prophylaxis, immunoglobulin replacement, and biologics such as anti-interferon-gamma antibodies address symptoms or downstream consequences but leave the fundamental amplification defect intact. A metabolic intervention that specifically takes the heat out of the chronically activated dendritic cell, without wholesale immune paralysis, would represent a genuinely different therapeutic modality: less an off switch than a thermostat adjustment.

The concept of targeting immunometabolism in interferonopathies has been building for several years. Metformin has shown benefit in mouse models of lupus, another interferon-driven condition, where it was found to reverse the inflammatory metabolic profile of patrolling monocytes. Metabolic reprogramming is also being explored in Behçet’s disease, systemic lupus erythematosus, and the rare monogenic interferonopathies such as Aicardi-Goutières syndrome. The appeal of repurposing metformin is obvious: the drug has an unmatched safety record across hundreds of millions of patient-years, is inexpensive, is available generically worldwide, and has a well-characterized pharmacology. If its interferon-damping effects in STAT1 gain-of-function translate to patients, the barrier to clinical testing is remarkably low compared with the development of a bespoke inhibitor.

The study, led by Zuzana Parackova, Katerina Sabatkova, and Miloslav Kolarik with colleagues, published in Cell Death & Discovery in 2026 under the title “Metformin-mediated immunometabolic rewiring attenuates type I interferon-driven dendritic cell inflammation in STAT1 gain-of-function,” positions dendritic cells as the fulcrum of the disease. This cellular focus is scientifically well-motivated. Dendritic cells are among the most metabolically plastic cells in the immune system, and their activation state is tightly coupled to their metabolic state. When dendritic cells sense danger through pattern-recognition receptors, they upregulate glucose transporters and glycolytic enzymes within hours, a program that supports fatty acid synthesis, protein production, and the massive secretory output of an activated cell. In STAT1 gain-of-function, the constitutive interferon signal plausibly locks this program in place, and the new data indicate that metformin can unlock it. By inhibiting mitochondrial complex I and activating AMPK, the drug forces the cell to make an energetic trade-off, and under energetic constraint the expensive, interferon-driven inflammatory program is scaled back.

There are, of course, caveats that the researchers and clinicians will be weighing carefully. Evidence from patient-derived cells and cellular models, however rigorous, does not guarantee clinical efficacy. Dendritic cells in a dish behave differently from dendritic cells navigating inflamed tissue, and the doses of metformin achievable in patients, while sufficient to activate AMPK in many tissues, produce blood concentrations far below those used in many cell-culture experiments. There is also a question of whether partially suppressing mitochondrial respiration in patients who may already have tissue damage, including lung disease, could have unintended consequences. And because STAT1 gain-of-function affects many cell types, including T cells, B cells, and stromal cells, correcting dendritic cell behavior alone may not resolve every manifestation of the disease. Nonetheless, the mechanistic clarity of the finding is its strength: it identifies a specific, druggable node in the disease circuitry and demonstrates a measurable reduction in the defining pathological signal.

The broader significance of the study lies in its framing of metabolic state as a therapeutic target for genetic inflammatory disease. STAT1 gain-of-function is, at root, a signaling mutation, and the intuitive approach is to attack the signaling pathway. But cells are not wiring diagrams; they are economies. A constitutive interferon signal must be paid for, and it is paid for in glucose, in mitochondrial capacity, in biosynthetic precursors. A drug that changes the exchange rate, that makes inflammation metabolically expensive, can achieve what signaling blockers achieve through an entirely orthogonal route, and potentially with a different and milder side-effect profile. This is the promise of immunometabolism as a discipline: it converts chronic, self-sustaining inflammation from a signaling problem into a supply problem, and supply problems can often be solved with old, safe drugs.

For the families affected by STAT1 gain-of-function disease, a condition so rare that diagnosis often takes years and affected children may endure recurrent infections, autoimmunity, and organ complications before a genetic test names their illness, any credible path toward a repurposed oral therapy is welcome. Clinical trials of metformin in interferonopathies would be a logical next step, and the mechanistic data from this study provide the rationale and the biomarkers, interferon-stimulated gene expression and dendritic cell inflammatory output, that such trials would need. If the rewiring observed in the laboratory holds in patients, a drug discovered in the 1920s and dispensed daily for diabetes since the 1950s could add a chapter to its already remarkable history: taming the antiviral alarm that never shuts off.

The SP protein family, which includes well-characterized members such as SP100, has long been implicated in the host’s antiviral arsenal. SP100 is known to suppress viral genome transcription by localizing to promyelocytic leukemia (PML) nuclear bodies, sequestering viral components in transcriptionally repressive compartments. However, SP140 diverges from this mechanistic paradigm, forming distinct nuclear bodies that do not overlap with PML structures. Instead, SP140 nuclear bodies partially co-localize with nucleoli, as indicated by fibrillarin staining, suggesting a unique subnuclear niche that may underpin its specialized functions.

To investigate the antiviral potential of SP140, researchers engineered HA-tagged SP140 knock-in mice, allowing for precise localization and functional analysis of the endogenous protein. In bone marrow-derived macrophages (BMMs) from these mice, SP140 was confirmed to be expressed at physiological levels and retain its capacity to repress the interferon-beta gene (Ifnb1) following activation by the STING agonist DMXAA. Immunofluorescence assays revealed large SP140 nuclear bodies distinct from canonical PML bodies, spotlighting SP140 as a nuclear factor with a distinct role in shaping antiviral responses.

Crucially, the antiviral function of SP140 was demonstrated through infection experiments using MHV68-GFP, a murine gammaherpesvirus engineered to express GFP as a marker of infection. Compared with wild-type macrophages, those lacking SP140 exhibited significantly increased viral infection rates, confirming SP140’s role as an antiviral barrier. Notably, this effect operated independently of type I interferon receptor (IFNAR) signaling, as SP140-deficient cells lacking IFNAR showed even greater susceptibility, underscoring SP140’s antiviral activity as distinct from canonical interferon-mediated pathways.

The study also illuminated a compensatory mechanism whereby the absence of SP140 leads to increased levels of IFN-beta transcripts, mediated by the proteins RESIST1 and RESIST2. These factors stabilize interferon mRNA, heightening the type I interferon response in SP140-deficient macrophages. In triple knockout macrophages deficient in SP140, RESIST1, and RESIST2, viral susceptibility matched that observed in interferon receptor-deficient cells, implicating this pathway as a critical backup immune response that counters viral spread when SP140-mediated restriction is lost.

Extending beyond MHV68, the antiviral scope of SP140 revealed virus-specific effects. For murine cytomegalovirus (MCMV), a subtler restriction was observed in SP140-deficient macrophages, which depended on the presence of RESIST proteins and IFNAR, suggesting that SP140’s antiviral efficacy is modulated by distinct viral contexts. Similarly, infection experiments with Sendai virus, an RNA virus encoding GFP, demonstrated enhanced viral restriction in SP140-deficient cells relying on the RESIST-mediated interferon pathway, highlighting the nuanced interplay of antiviral effectors across diverse viral families.

At the heart of this study lies the proposal that SP140’s evolution toward repressing type I interferon (IFN-I) production may represent an adaptive mechanism to calibrate immune responses and prevent deleterious inflammation. While SP100 and related nuclear body proteins exert direct antiviral effects through genome silencing within PML bodies, SP140 appears to fulfill a dual role: suppressing excessive interferon induction while maintaining direct antiviral activity through its unique nuclear localization. This balance restrains viral replication yet avoids harmful overactivation of interferon signaling pathways.

Interestingly, viruses have evolved strategies to disrupt nuclear body functions to evade antiviral restrictions. The study suggests that the SP140–RESIST axis embodies an evolutionary countermeasure, where the loss of nuclear body integrity due to viral effectors triggers a secondary, effector-triggered immunity response. This phenomenon, extensively characterized in plants, provides a ‘backup’ defense in mammals by stabilizing interferon mRNA and sustaining antiviral states despite viral attempts to dismantle primary defenses.

The molecular identity of RESIST1 and RESIST2 as RNA-binding proteins that enhance interferon mRNA stability sheds light on a pivotal regulatory checkpoint. Their involvement in fine-tuning interferon expression downstream of SP140 underscores the multilayered control of antiviral immunity, where nuclear architectural components intersect with cytoplasmic post-transcriptional regulators to sculpt an effective defense landscape.

Methodologically, the use of precise genetic models such as HA-tagged SP140 knock-in mice and combined knockouts of SP140 with RESIST and IFNAR demonstrates the power of targeted gene editing in dissecting complex immunological phenomena. Flow cytometry-based quantification of GFP-expressing viruses in bone marrow-derived macrophages provided robust evidence of SP140’s antiviral capabilities and the compensatory role of RESIST proteins, ensuring the data’s reliability and relevance.

Taken together, these findings refashion our understanding of nuclear body proteins in antiviral immunity, placing SP140 at a crossroads between chromatin-level repression and interferon-mediated antiviral amplification. The dichotomy of SP140’s functions hints at a sophisticated evolutionary dance between host and pathogen, where immune surveillance and viral evasion continuously sculpt the cellular environment.

The elucidation of the SP140–RESIST pathway opens potential avenues for therapeutic intervention aimed at modulating interferon responses and enhancing antiviral defenses, particularly in infections where nuclear body integrity is compromised. It also paves the way for deeper explorations into effector-triggered immunity in mammals, an area previously overshadowed by plant immunity research but now gaining recognition as a vital vertebrate defense strategy.

In sum, the SP140 protein exemplifies the intricate nuclear choreography underlying antiviral defense, balancing the suppression of potentially damaging interferon production with direct repression of viral genomes. The discovery of its partnership with RESIST proteins in stabilizing interferon mRNA adds a nuanced layer to the immune response, reinforcing the concept that combating viruses requires a multi-tiered and adaptable approach.

As the scientific community unravels the molecular dialogues within nuclear bodies, studies such as this redefine the boundaries of innate immunity, highlighting the crosstalk between nuclear architecture, mRNA stability, and metal signaling. In the ongoing war against viral pathogens, SP140 and its associated pathways represent new frontiers of knowledge and potential antiviral targets, promising advancements in immunology and virology alike.

Subject of Research:
Regulation of interferon mRNA stability and antiviral immunity mediated by SP140 and RESIST proteins.

Article Title:
SP140–RESIST pathway regulates interferon mRNA stability and antiviral immunity.

Article References:
Witt, K.C., Dziulko, A., An, J. et al. SP140–RESIST pathway regulates interferon mRNA stability and antiviral immunity. Nature (2025). https://doi.org/10.1038/s41586-025-09152-2

Image Credits:
AI Generated

Bladder cancer remains one of the most commonly diagnosed malignancies worldwide, with high recurrence rates and limited treatment options in advanced stages. The immune microenvironment plays a pivotal role in cancer progression and response to therapy, with interferon signaling pathways being a central component of the antitumor immune response. However, tumor cells frequently develop sophisticated mechanisms to evade immune surveillance, often through the modulation of interferon signaling, thereby fostering tumor growth and resistance to immune-mediated eradication.

The study spearheaded by Barnaba, Franzese Canonico, Helmer-Citterich, and colleagues focuses on the identification and characterization of LEADR, a long non-coding RNA directly regulated by the transcription factor p63, which is known for its diverse roles in epithelial development and cancer. LEADR emerges as a critical molecular effector capable of attenuating interferon signaling, enabling bladder cancer cells to dampen immune responses and sustain malignant phenotypes.

LEADR is a fascinating addition to the burgeoning field of lncRNAs, which have rapidly gained attention for their nuanced regulatory functions in gene expression. Unlike protein-coding genes, lncRNAs modulate cellular processes through interactions with DNA, RNA, and proteins, fine-tuning signaling networks and transcriptional landscapes with remarkable specificity. LEADR exemplifies such complexity by targeting key nodes within the interferon pathway, thereby modulating the downstream effects that dictate cellular immunity.

Mechanistically, the research explores how LEADR expression is directly under the transcriptional control of p63, a member of the p53 family well-recognized for its tumor-suppressive and oncogenic roles depending on cellular context. Using sophisticated molecular biology techniques, including chromatin immunoprecipitation sequencing and RNA interference, the team demonstrated a clear regulatory axis from p63 to LEADR, linking epithelial differentiation signals with immune modulation.

The dampening effect of LEADR on interferon signaling appears to be mediated through its interaction with key transcriptional regulators of interferon-stimulated genes (ISGs). By repressing ISG expression, LEADR effectively weakens the antiviral and antiproliferative responses typically induced by interferon pathways, allowing bladder cancer cells to escape immune detection and thrive in an otherwise hostile microenvironment.

Interestingly, the functional consequences of LEADR-mediated suppression of interferon signaling extend beyond immune evasion. The study uncovers that LEADR also modulates factors involved in cell proliferation, apoptosis resistance, and metastatic potential, underscoring its multifaceted role in tumor biology. This pleiotropic impact positions LEADR as a linchpin in the complex crosstalk between cancer cells and their immune milieu.

Clinical correlations further reinforce the biological importance of LEADR. Data gathered from patient-derived tumor samples revealed that higher LEADR expression levels are associated with more aggressive bladder cancer phenotypes and poorer prognoses. These findings suggest that LEADR might serve as a potential prognostic biomarker, helping clinicians stratify patients based on their tumor’s immune modulatory capacity.

From a therapeutic standpoint, targeting LEADR offers a promising strategy to reinvigorate interferon signaling in bladder cancer. The researchers propose that suppressing LEADR expression or function could restore immune surveillance mechanisms, enhancing the efficacy of existing immunotherapies such as immune checkpoint inhibitors. This approach resonates with the ongoing paradigm shift in oncology toward combinatorial treatments that unleash the full potential of the immune system against tumors.

Moreover, the study utilized advanced in vitro and in vivo models to validate LEADR’s role in tumor immune evasion. Bladder cancer cell lines with genetically inhibited LEADR showed increased sensitivity to interferon treatment and exhibited reduced tumorigenicity when implanted in immunocompetent mice models. These preclinical results lay the groundwork for future clinical trials targeting LEADR-related pathways.

In the broader context of cancer biology, this research highlights the intricate interplay between non-coding RNAs and immune signaling pathways, emphasizing the importance of considering non-protein-coding elements in the tumor microenvironment. By unveiling LEADR’s pivotal function, the study sets a precedent for further investigations into lncRNA-mediated regulation of immune responses in various cancer types.

The discovery also underscores the versatility and complexity of p63’s regulatory network. As a master regulator in epithelial tissues, p63’s influence extends beyond cell differentiation and proliferation, encompassing immune regulation through lncRNA intermediates such as LEADR. This expanded understanding of p63’s functions can inform new therapeutic angles in epithelial cancers, not limited to the bladder.

Furthermore, the research leverages cutting-edge genomic and transcriptomic technologies, reflecting an era where high-throughput sequencing and computational analyses are indispensable tools in decoding cancer’s molecular underpinnings. Such integrative approaches allow researchers to pinpoint subtle yet impactful regulatory molecules like LEADR within vast genomic landscapes.

Importantly, the implications of LEADR’s modulation of interferon signaling resonate beyond cancer. Interferon pathways are central to antiviral defenses and immune homeostasis, and their dysregulation contributes to a spectrum of diseases. Understanding how lncRNAs like LEADR fine-tune these pathways can illuminate novel aspects of immune regulation with potential relevance in autoimmune and infectious diseases.

As the scientific community digests these findings, questions naturally arise regarding the mechanisms controlling LEADR’s expression in normal versus cancerous tissues, and how its activity might be influenced by the tumor microenvironment, including inflammatory cues and cellular stressors. Addressing these questions could deepen our insight into dynamic tumor-immune interactions.

To conclude, the identification of LEADR as a p63-targeted lncRNA that attenuates interferon signaling offers a profound advance in our comprehension of bladder cancer biology. This work illustrates the powerful role of non-coding RNAs in orchestrating immune evasion, revealing novel molecular targets to disrupt cancer’s defense tactics. As researchers continue to unravel the complexities of tumor immunity, discoveries like LEADR pave the way toward more effective, immune-informed cancer therapies that could transform patient outcomes globally.

Subject of Research: Bladder cancer molecular biology, long non-coding RNA regulation, interferon signaling, tumor immune evasion

Article Title: LEADR, a p63 target, dampens interferon signalling in bladder cancer

Article References:
Barnaba, D., Franzese Canonico, M., Helmer-Citterich, M. et al. LEADR, a p63 target, dampens interferon signalling in bladder cancer. Cell Death Discov. 11, 264 (2025). https://doi.org/10.1038/s41420-025-02546-1

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41420-025-02546-1